(63 days)
Not Found
No
The description focuses on the mechanical and material properties of the tissue expander and a magnetic locator. There is no mention of AI or ML in the intended use, device description, or performance studies.
Yes.
The device is used for breast reconstruction after mastectomy and for the correction of an underdeveloped breast, which are therapeutic interventions.
No
The device description clearly states that the CPX™ Control Breast Tissue Expander is used for breast reconstruction, scar revision, and tissue defect procedures. It is an implantable device designed for temporary subcutaneous or submuscular implantation and functions as a tissue expander. There is no mention of it being used to diagnose any medical condition, but rather for physical reconstruction.
No
The device description clearly outlines physical components made of silicone elastomer and includes accessories like a magnetic locator and infusion set, indicating it is a hardware device, not software-only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for breast reconstruction, correction of underdeveloped breasts, scar revision, and tissue defect procedures. These are surgical procedures performed on the body.
- Device Description: The device is a physical implant (silicone elastomer shell) intended for subcutaneous or submuscular implantation. It is used to physically expand tissue.
- Mechanism of Action: The device works by being filled with saline solution to stretch the surrounding tissue. This is a mechanical process, not a diagnostic test performed on samples outside the body.
- Lack of Diagnostic Elements: There is no mention of the device being used to analyze biological samples (blood, urine, tissue, etc.) or to provide diagnostic information about a patient's health condition.
IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This device does not fit that description.
N/A
Intended Use / Indications for Use
The CPX(TM) Control Breast Tissue Expanders can be utilized for breast reconstruction after mastectomy, correction of an underdeveloped breast, scar revision and tissue defect procedures. The expander is intended for temporary subcutaneous or submuscular implantation and is not intended for use beyond six months.
Product codes
LCJ
Device Description
The CPX™ Control Breast Tissue Expander consists of a silicone elastomer shell, with interior structural elements to allow for directional expansion in the lower pole of the device. The device has an integral, silicone elastomer, magnetically detectable injection port. The injection port also incorporates a BUFFERZONE® area with self-sealing technology which is attached to the inside of the anterior surface of the device. The BUFFERZONE® is intended to minimize and/or prevent leakage in the event of an accidental needle puncture.
Identification of the injection port site is accomplished by use of the CENTERSCOPE® Magnetic Injection Port Locator, which is provided with the Tissue Expander. When the Centerscope device is placed on top of the skin, the magnetic arm points to the center of the tissue expander's injection dome. Injections into the injection dome area are made using the provided infusion needle set to inject sterile, pyrogen-free Sodium Chloride U.S.P. Solution.
The MENTOR CPX™ Control Breast Tissue Expander incorporates suture tabs to provide surgeons with the option to attach the device to surrounding tissue for enhanced device stability.
The CPX Control devices are provided sterile in various styles and sizes.
The following accessories are packaged with the CPX Control Tissue Expander:
- . Centerscope Magnetic Injection Port Finder
- Winged Infusion Set ●
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
breast
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Biocompatibility Testing:
The CPX Control Breast Tissue Expander is an implantable device, the contact category according to ISO10993-1 is: Implant, tissue contacting, permanent (> 30 days). All materials used in the CPX Control tissue expander are identical to the materials used in the predicate device.
Mechanical Testing:
Mechanical testing was conducted in accordance with Draft Guidance for Industry and Staff -Class II Special Controls Guidance for Tissue Expanders, issued December 22, 2008 and ASTM F1441-03, Standard Specification for Soft-Tissue Expanders. The following mechanical testing was performed:
- Elongation ●
- . Tensile Strength
- Break Force .
- . Joint Testing
- Overexpansion .
- Injection Valve Competency ●
All mechanical performance testing results met their pre-determined acceptance criteria, thus demonstrating that the proposed device is substantially equivalent to the predicate device.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
N/A
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles a stylized eagle or bird in flight, composed of three interconnected human profiles facing to the right.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
December 19, 2014
Mentor Worldwide LLC Ms. Manchi Cheung Regulatory Manager 201 Mentor Drive Santa Barbara, California 93111
Re: K142998
Trade/Device Name: CPX (TM) Control Breast Tissue Expanders Regulatory Class: Unclassified Product Code: LCJ Dated: October 16, 2014 Received: October 17, 2014
Dear Ms. Cheung:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Binita S. Ashar -S
Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K142998
Device Name CPX (TM) Control Breast Tissue Expanders
Indications for Use (Describe)
The CPX(TM) Control Breast Tissue Expanders can be utilized for breast reconstruction after mastectomy, correction of an underdeveloped breast, scar revision and tissue defect procedures. The expander is intended for temporary subcutaneous or submuscular implantation and is not intended for use beyond six months.
Type of Use (Select one or both, as applicable)
2 Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) SUMMARY
In accordance with 21 CFR 807.87(h) and (21 CFR 807.92) the 510(k) Summary for the Mentor CPX™ Control Breast Tissue Expanders is provided below.
I. SUBMITTER Mentor Worldwide LLC 201 Mentor Drive Santa Barbara, CA 93111
Contact Person: Manchi Cheung Regulatory Manager Phone: 805 -879-6790 Fax: 805-879-6167 mcheung3@its.jnj.com
Date Prepared: October 16, 2014
II. DEVICE
| Name of Device: | Mentor CPX TM Control Breast Tissue Expanders |
|---|---|
| Common Device Name: | Expander, Skin, Inflatable |
| Classification | |
| Regulation: | Unclassified, Pre-Amendment |
| Panel: | General & Plastic Surgery |
| Product Code: | LCJ |
III. PREDICATE DEVICE
K130813, Mentor CPX4 Breast Tissue Expanders and Mentor CPX 4 Breast Tissue Expanders with Suture Tabs This predicate has not been subjected to a design-related recall.
No reference devices were used in this submission.
IV. DEVICE DESCRIPTION
The CPX™ Control Breast Tissue Expander consists of a silicone elastomer shell, with interior structural elements to allow for directional expansion in the lower pole of the device. The device has an integral, silicone elastomer, magnetically detectable injection port. The injection port also incorporates a BUFFERZONE® area with self-sealing technology which is attached to the inside of the anterior surface of the device. The BUFFERZONE® is intended to minimize and/or prevent leakage in the event of an accidental needle puncture.
Identification of the injection port site is accomplished by use of the CENTERSCOPE®
4
Magnetic Injection Port Locator, which is provided with the Tissue Expander. When the Centerscope device is placed on top of the skin, the magnetic arm points to the center of the tissue expander's injection dome. Injections into the injection dome area are made using the provided infusion needle set to inject sterile, pyrogen-free Sodium Chloride U.S.P. Solution.
The MENTOR CPX™ Control Breast Tissue Expander incorporates suture tabs to provide surgeons with the option to attach the device to surrounding tissue for enhanced device stability.
The CPX Control devices are provided sterile in various styles and sizes.
The following accessories are packaged with the CPX Control Tissue Expander:
- . Centerscope Magnetic Injection Port Finder
- Winged Infusion Set ●
V. INDICATIONS FOR USE
The CPX™ Control Breast Tissue Expander can be utilized for breast reconstruction after mastectomy, correction of an underdeveloped breast, scar revision and tissue defect procedures. The expander is intended for temporary subcutaneous or submuscular implantation and is not intended for use beyond six months.
VI. COMPARISON OF TECHOLOGICAL CHARACTERISTICS WITH PREDICATE
The technological principle for both the proposed and predicate devices is the same. Both devices expansion are based on incremental filling of a silicone shell with saline fluid to stretch the surrounding tissue. Filling is achieved via an integral injection dome with needle guard, and a magnetic injection finder to locate the dome.
The proposed and predicate devices are based on the following same technological elements:
- Same intended use
- Same operating principle ●
- Same materials, same dimensional and volume ranges
- Same integral injection Dome with neodymium needle guard
- . Same BUFFERZONE® area with self-sealing technology around the injection dome to prevent accidental needle punctures
- . Same suture tabs to attach device to surrounding tissue
- Same use of reinforced silicone sheeting applied to areas of the device for directional expansion in the lower pole
- . Compliance with the same recognized standards and test requirements.
The following additional design features are included in the proposed device. These design features are made using materials featured in the predicate device.
- . An additional reinforced silicone sheeting is applied to the interior perimeter of the shell, adjacent to the base
- . Use of tethering elements inside the shell to further minimize expansion in the upper pole and the area around the base, providing additional directional expansion to the lower pole.
5
VII. PERFORMANCE DATA
Biocompatibility Testing:
The CPX Control Breast Tissue Expander is an implantable device, the contact category according to ISO10993-1 is: Implant, tissue contacting, permanent (> 30 days). All materials used in the CPX Control tissue expander are identical to the materials used in the predicate device.
Mechanical Testing:
Mechanical testing was conducted in accordance with Draft Guidance for Industry and Staff -Class II Special Controls Guidance for Tissue Expanders, issued December 22, 2008 and ASTM F1441-03, Standard Specification for Soft-Tissue Expanders. The following mechanical testing was performed:
- Elongation ●
- . Tensile Strength
- Break Force .
- . Joint Testing
- Overexpansion .
- Injection Valve Competency ●
All mechanical performance testing results met their pre-determined acceptance criteria, thus demonstrating that the proposed device is substantially equivalent to the predicate device.
VIII. CONCLUSION
The CPX Control Breast Tissue Expander is substantially equivalent to the legally marketed predicate device, CPX4 Breast Tissue Expander and CPX4 Breast Tissue Expander with Suturing Tabs (K130813). The CPX Control Breast Tissue Expander has the same indications for use, operating principle and technological characteristics as the predicate device. Performance evaluations demonstrate that the subject device is substantially equivalent to the predicate device.